New TB Vaccine Goes on Trial

Medical Authors and Editors: Barbara K. Hecht, Ph.D. and Frederick Hecht, M.D.

Jan. 27, 2004 -- A promising new vaccine for tuberculosis (TB) is about to go into a clinical trial, according to a press release (below) from the National Institute of Allergy and Infectious Diseases (NIAID).

The new vaccine combines two TB proteins that stimulate strong immune responses in humans. These proteins were identified by screening blood samples from people who never became ill with tuberculosis despite long-term infection with the bacteria Mycobacterium tuberculosis, which causes the disease.

The two TB proteins were fused by recombinant DNA technology, and then combined with adjuvants, substances that further boost the immune system's response to the vaccine.

The New Vaccine in Perspective

Anthony S. Fauci, MD, Director of NIAID provided perspective on the new vaccine.


Health Solutions From Our Sponsors